The ELVIS study: Medium and long‐term Efficacy of LVIS EVO stent‐assisted coil embolisation for unruptured saccular intracranial aneurysms—A tertiary single‐centre experience
Journal of Medical Imaging and Radiation Oncology · 2025
DOI: 10.1111/1754-9485.13820 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, 2025. Verfasst von Krishna Pranathi Settipalli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Intracranial Aneurysm, Embolization, Therapeutic, Stents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
The LVIS EVO (MicroVention ® ) is a braided stent designed to assist coil embolisation of intracranial aneurysms. It offers several structural innovations over previous and currently available braided, and laser‐cut, stents that are theorised to improve procedural success. This retrospective audit aims to determine the success and complication rates of LVIS EVO‐assisted coil embolisation in unruptured saccular aneurysms at a tertiary neurovascular referral centre in Queensland, Australia.
Methods
The medical records of all patients who underwent elective LVIS EVO‐assisted coil embolisation at our institution between 2020 and 2024 were reviewed. Clinical and radiologic outcomes, including occlusion rate, occlusion grade (modified Raymond Roy classification—MRRC), complications, recurrence rate, and change in modified Rankin scale (mRS) were recorded, alongside aneurysm characteristics and technical procedural details.
Results
Of 29 cases, 2 were excluded due to complex aneurysms requiring off‐label LVIS EVO use. Twenty‐seven (27) saccular aneurysms in 26 patients (18 female; 8 male) were included. Most (22/27) involved the anterior cerebral artery (ACA), primarily the anterior communicating artery (18/27). Complete occlusion was seen in 55.6% (15/27) of cases immediately post‐procedure, in 85.2% (23/27) at 3 months, and in 84.2% (16/19) at a median of 12‐months post‐procedure. A recurrence was seen in 7.4% (2/27) of patients. No procedural or long‐term complications, and no significant changes in 90‐day mRS, were noted.
Conclusion
Our results show 100% technical success reflecting existing literature and contribute further by providing data on medium to long‐term success rates with LVIS EVO‐assisted coil embolisation for unruptured saccular aneurysms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Imaging, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia.
- Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
ORCID-Profile: Krishna Pranathi Settipalli
Zitieren
APA
Settipalli, K. P., Dunkerton, S., Hilton, J., Aw, G., Lock, G., Mitchell, K., & Coulthard, A. (2025). The ELVIS study: Medium and long‐term Efficacy of LVIS EVO stent‐assisted coil embolisation for unruptured saccular intracranial aneurysms—A tertiary single‐centre experience. Journal of Medical Imaging and Radiation Oncology. https://doi.org/10.1111/1754-9485.13820
Vancouver
Settipalli KP, Dunkerton S, Hilton J, Aw G, Lock G, Mitchell K, et al. The ELVIS study: Medium and long‐term Efficacy of LVIS EVO stent‐assisted coil embolisation for unruptured saccular intracranial aneurysms—A tertiary single‐centre experience. Journal of Medical Imaging and Radiation Oncology. 2025. doi:10.1111/1754-9485.13820
BibTeX
@article{Settipalli2025,
author = {Settipalli, Krishna Pranathi and Dunkerton, Sophie and Hilton, John and Aw, Grace and Lock, Gregory and Mitchell, Kenneth and Coulthard, Alan},
title = {The ELVIS study: Medium and long‐term Efficacy of LVIS EVO stent‐assisted coil embolisation for unruptured saccular intracranial aneurysms—A tertiary single‐centre experience},
journal = {Journal of Medical Imaging and Radiation Oncology},
year = {2025},
doi = {10.1111/1754-9485.13820}
}
EUVIMED